Advance Clinical Progress with Diagnostics & Harness the Vaginal Microbiome for Reproductive Health, Endometriosis & Non-Cancer Indications

Through many years of neglect, the field of women’s health has long been under researched and underfunded, resulting in the misdiagnosis and mistreatment of females across the world. From invasive diagnostic measures for endometriosis cases to outdated clinical techniques to determine an imbalance in vaginal microbiota, women have long felt under-represented across the health care system regarding indications of the reproductive system.

A combination of shared frustration and collaborative passion from industry pioneers has reignited the momentum across the field, shifting the investment spotlight to shine bright on women’s health biotech and pharma. 2024 has already witnessed Freya Bioscience raising $38 million for microbial immunotherapies, as well as Heranova Lifesciences debuting $13.5 million in seed funding for clinical solutions across women’s health. The time is now for the community to unite and drive clinical progress across women’s health, paving the way for an increase in market access and hope for millions of women currently suffering across the globe.

The Women’s Health Therapeutics & Diagnostics Summit presents the ultimate platform to combine forces across biotech and biopharma, showcasing the industry trailblazers to drive innovation and clinical progress across a range of disease indications. From endometriosis to bacterial vaginosis to infertility, pre-term birth, menopause and more, the need for in-depth conversations surrounding current standard of care, technological advancements and innovative pipeline developments has never been higher.

It is now imperative for industry to unite, with the likes of Ferring Pharmaceuticals, Organon, Hera Biotech, Evvy, Gynica, Freya Bioscience and more sharing case studies and data-driven insights, bringing the latest technological developments to the fore and overcoming the current translational challenges. A collective goal of propelling novel treatments and diagnostic tools to market in both a safe and efficacious manner remains pivotal, striving towards a personalized medicines approach.

Remain central to the conversation and hear from the world leaders in the field as 60+ women’s health leads, clinical heads and experts from biotech and biopharma touch down in Boston to continue the revolution.

For more details about the program, speaker faculty or pricing and discounts, download the brochure.

Industry-leading speakers include:

icon 1 home


how leading forces across women’s health are collaborating to create the new wave of diagnostic and therapeutic tools to fuel the future of women’s health

icon 2 home


your understanding of the current challenges, strategies, and solutions to revolutionize your innovative approach to diagnose and treat previously understudied disease indications including endometriosis, bacterial vaginosis, infertility, menopause and more

icon 3 home


with your community and peers from leading pharma and biotech companies seeking the best solution to drive more products to the clinic and beyond, building lasting connections and complementary collaboration

The huge energy and enthusiasm across women’s health always strikes me, voicing the need for change, and now is the time to do that

Freya Biosciences  

‘’Women’s health scientific innovations face unique challenges, that require a community-wide discussion’’

Hera Biotech 

The science currently is super exciting in women’s health, I am very interested to see the work being done across industry with varying biotherapeutic products in clinic

Ferring Pharmaceuticals